Levetiracetam
Product Images NDC 70934-352

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70934-352). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

70934 352 30 Master Bottle Label Approval Rev A 05 19

Levetiracetam Tablets USP 500 mg label with NDC 70934-352-30. The label indicates 30 tablets per package, Rx Only, with storage instructions for controlled room temperature (15°-30°C). Manufactured by Denton Pharma, Inc. dba Northwind Pharmaceuticals. Includes standard warnings and lot number, expiration date, and manufacturing details.*

FDA Label Image

D0b54345 900c 42f9 A3a2 D81e740d85aa 01

A formula for calculating the total daily dose of Levetiracetam oral solution, showing that the total daily dose in mL per day equals the product of the daily dose in mg/kg/day and the patient weight in kilograms, divided by the concentration of 100 mg/mL.*

FDA Label Image

D0b54345 900c 42f9 A3a2 D81e740d85aa 02

A mathematical formula panel showing how to calculate creatinine clearance (CLcr) adjusted for body surface area (BSA). It includes the formula using age, weight, serum creatinine, and a factor for female patients, followed by an adjustment for BSA with a multiplication factor of 1.73 divided by the subject's BSA in square meters.*

FDA Label Image

D0b54345 900c 42f9 A3a2 D81e740d85aa 03

Chemical structure of levetiracetam, showing the molecular arrangement with a pyrrolidone ring attached to an ethyl group and amide functional group.*

FDA Label Image

D0b54345 900c 42f9 A3a2 D81e740d85aa 04

A bar graph comparing the percentage of patients among three groups: Placebo with 7.4%, Levetiracetam 1000 mg/day with 37.1%, and Levetiracetam 3000 mg/day with 39.6%. The y-axis represents the percentage of patients, and each bar shows the number of patients in the group below the category on the x-axis.*

FDA Label Image

D0b54345 900c 42f9 A3a2 D81e740d85aa 05

Bar chart comparing the percentage of patients among three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Each bar is labeled with the percentage and patient count for each group.*

FDA Label Image

D0b54345 900c 42f9 A3a2 D81e740d85aa 06

A bar graph comparing the percentage of patients between a placebo group (14.4%) and a Levetiracetam 3000 mg/day group (39.4%). The y-axis represents the percentage of patients, and an asterisk marks the Levetiracetam bar indicating statistical significance.*

FDA Label Image

D0b54345 900c 42f9 A3a2 D81e740d85aa 07

Bar chart comparing the percentage of patients between Placebo (N=97) and Levetiracetam (N=101). The Placebo group shows 19.6% of patients, while the Levetiracetam group shows 44.6%. The y-axis represents the percentage of patients from 0% to 45%.*

FDA Label Image

D0b54345 900c 42f9 A3a2 D81e740d85aa 08

A bar chart comparing the percentage of patients between two groups: Placebo and Levetiracetam. The y-axis represents the percentage of patients from 0% to 45%. The Placebo group (N=51) has 19.6% patients, while the Levetiracetam group (N=58) has 43.1% patients. An asterisk is shown above the Levetiracetam bar, indicating statistical significance.*

FDA Label Image

D0b54345 900c 42f9 A3a2 D81e740d85aa 09

Bar graph comparing the percentage of patients responding to treatment with Placebo versus Levetiracetam. The y-axis shows percentage of patients from 0% to 100%. The Placebo group (N=84) shows 45.2%, and the Levetiracetam group (N=79) shows 72.2% with an asterisk marked above the Levetiracetam bar, indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.